Related Experiment Video
Updated: Jul 4, 2026
High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
Published on: July 17, 2014
Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium
David E Arnot1, David R Cavanagh, Edmond J Remarque
1Centre for Medical Parasitology, Institute for International Health, Immunology and Microbiology, University of Copenhagen, Denmark. d.e.arnot@cmp.dk
Abstract:
Immunogenicity testing of Plasmodium falciparum antigens being considered as malaria vaccine candidates was undertaken in rabbits. The antigens compared were recombinant baculovirus MSP-1(19) and five Pichia pastoris candidates, including two versions of MSP-1(19), AMA-1 (domains I and II), AMA-1+MSP-1(19), and fused AMA-1/MSP-1(19)). Animals were immunized with equimolar amounts of each antigen, formulated in Montanide ISA720. The specificities and titers of antibodies were compared using immunofluorescence assays and enzyme-linked immunosorbent assay (ELISA). The antiparasite activity of immunoglobulin G (IgG) in in vitro cultures was determined by growth inhibition assay, flow cytometry, lactate dehydrogenase assay, and microscopy. Baculovirus MSP-1(19) immunizations produced the highest parasite-specific antibody titers in immunofluorescence assays. In ELISAs, baculovirus-produced MSP-1(19) induced more antibodies than any other single MSP-1(19) immunogen and three times more MSP-1(19) specific antibodies than the AMA-1/MSP-1(19) fusion. Antibodies induced by baculovirus MSP-1(19) gave the highest levels of growth inhibition in HB3 and 3D7 parasite cultures, followed by AMA-1+MSP-1(19) and the AMA-1/MSP-1(19) fusion. With the FCR3 isolate (homologous to the AMA-1 construct), antibodies to the three AMA-1-containing candidates gave the highest levels of growth inhibition at high IgG concentrations, but antibodies to baculovirus MSP-1(19) inhibited as well or better at lower IgG concentrations. The two P. pastoris-produced MSP-1(19)-induced IgGs conferred the lowest growth inhibition. Comparative analysis of immunogenicity of vaccine antigens can be used to prioritize candidates before moving to expensive GMP production and clinical testing. The assays used have given discriminating readouts but it is not known whether any of them accurately reflect clinical protection.
Insights
Comparing malaria vaccine candidates in rabbits, baculovirus-produced MSP-1(19) showed superior immunogenicity, inducing higher antibody titers and greater parasite growth inhibition compared to Pichia pastoris candidates.
Area of Science:
- Malariology
- Vaccinology
- Immunology
Background:
- Developing an effective malaria vaccine is a global health priority, requiring robust immunogenicity testing of candidate antigens.
- Plasmodium falciparum antigens, including MSP-1(19) and AMA-1, are key targets for malaria vaccine development.
- Different expression systems (baculovirus, Pichia pastoris) can impact antigen immunogenicity and vaccine efficacy.
Purpose of the Study:
- To compare the immunogenicity of Plasmodium falciparum antigens produced in different systems (baculovirus vs. Pichia pastoris) as malaria vaccine candidates.
- To evaluate antibody responses and in vitro antiparasitic activity induced by recombinant antigens in a rabbit model.
- To inform the prioritization of malaria vaccine candidates for further development.
Main Methods:
- Rabbits were immunized with equimolar amounts of baculovirus-produced MSP-1(19) and five Pichia pastoris candidates (MSP-1(19), AMA-1, AMA-1+MSP-1(19), fused AMA-1/MSP-1(19)) in Montanide ISA720.
- Antibody specificity and titers were assessed using immunofluorescence assays and ELISA.
- In vitro antiparasite activity was measured by growth inhibition assays, flow cytometry, LDH assay, and microscopy.
Main Results:
- Baculovirus-produced MSP-1(19) elicited the highest parasite-specific antibody titers and significantly greater antibody levels in ELISA compared to other MSP-1(19) immunogens.
- Antibodies induced by baculovirus MSP-1(19) demonstrated the highest in vitro growth inhibition across multiple parasite strains (HB3, 3D7, FCR3), especially at lower IgG concentrations.
- Pichia pastoris-produced MSP-1(19) induced the lowest levels of growth inhibition, while AMA-1-containing candidates showed efficacy against the homologous FCR3 strain.
Conclusions:
- Recombinant baculovirus-derived MSP-1(19) exhibits superior immunogenicity and in vitro efficacy compared to Pichia pastoris-produced antigens, making it a promising malaria vaccine candidate.
- Comparative immunogenicity testing in animal models is crucial for prioritizing vaccine candidates before costly clinical trials.
- While current assays provide discriminating readouts, their correlation with clinical protection against malaria remains to be determined.
